According to Zacks, “Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, principally in the United States. Greenbrook TMS Inc. is based in TORONTO. “
A number of other research analysts have also recently weighed in on GBNH. Clarus Securities lowered their price objective on Greenbrook TMS from C$8.25 to C$7.50 in a research report on Monday, April 4th. Bloom Burton reissued a “buy” rating on shares of Greenbrook TMS in a report on Monday, April 4th. Stifel Nicolaus lowered their price target on Greenbrook TMS from C$19.00 to C$10.00 in a report on Tuesday, May 17th. Finally, Canaccord Genuity Group cut Greenbrook TMS to a “buy” rating in a report on Monday, February 7th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $13.04.
Greenbrook TMS (NASDAQ:GBNH – Get Rating) last posted its quarterly earnings data on Friday, May 13th. The company reported ($0.44) earnings per share for the quarter. Greenbrook TMS had a negative net margin of 46.27% and a negative return on equity of 157.80%. The company had revenue of $13.07 million for the quarter, compared to analysts’ expectations of $11.70 million. During the same period in the previous year, the firm earned ($0.56) earnings per share. Sell-side analysts predict that Greenbrook TMS will post -1.26 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in GBNH. Masters Capital Management LLC grew its position in Greenbrook TMS by 55.6% in the 4th quarter. Masters Capital Management LLC now owns 700,000 shares of the company’s stock valued at $2,954,000 after acquiring an additional 250,000 shares during the last quarter. Royce & Associates LP grew its position in Greenbrook TMS by 8.0% in the 4th quarter. Royce & Associates LP now owns 223,500 shares of the company’s stock valued at $977,000 after acquiring an additional 16,598 shares during the last quarter. AdvisorShares Investments LLC grew its position in Greenbrook TMS by 61.3% in the 1st quarter. AdvisorShares Investments LLC now owns 103,562 shares of the company’s stock valued at $389,000 after acquiring an additional 39,348 shares during the last quarter. Virtu Financial LLC bought a new position in Greenbrook TMS in the 4th quarter valued at $288,000. Finally, Bank of Montreal Can bought a new position in Greenbrook TMS in the 1st quarter valued at $123,000. 16.73% of the stock is currently owned by hedge funds and other institutional investors.
About Greenbrook TMS (Get Rating)
Greenbrook TMS Inc, together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services.
- Get a free copy of the StockNews.com research report on Greenbrook TMS (GBNH)
- CrowdStrike earnings and revenue beat forecasts, stock falls
- Ryder System, Inc: The Most Interesting Play In Logistics
- This Isn’t A Buyable Bottom For Stocks
- Macys Stock is Ready to Buy
- First Solar Stock is Ready to Shine
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Greenbrook TMS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenbrook TMS and related companies with MarketBeat.com's FREE daily email newsletter.